Dociparstat sodium

DRUG3 trials

Sponsors

Jazz Pharmaceuticals

Conditions

Acute Lung InjuryAcute Myeloid LeukemiaCoronavirus Disease 2019 (COVID-19)Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Phase 1

A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia

CompletedNCT02056782

Jazz PharmaceuticalsAcute Myeloid Leukemia

Start: 2013-12-31End: 2015-06-30Updated: 2023-02-21

Phase 2

Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

CompletedNCT02873338

Jazz PharmaceuticalsAcute Myeloid Leukemia

Start: 2016-08-31End: 2019-06-30Updated: 2023-09-07

Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

TerminatedNCT04389840

Jazz PharmaceuticalsAcute Lung Injury, Coronavirus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Start: 2020-07-08End: 2021-05-20Updated: 2022-08-30

Related Papers

Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19.

2020-10-2715 citations

A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML).

Journal of Clinical Oncology2019-05-2011 citations

O-desulfated heparin and chemotherapy for the treatment of AML.

Journal of Clinical Oncology2015-05-203 citations